Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Pluristem Soars Most in Four Months on Results of Cell Study

Nov. 3 (Bloomberg) -- Pluristem Therapeutics Inc. surged the most in more than four months after the developer of cell-therapy products said a clinical trial of its PLX-PAD cells to treat critical limb ischemia met all the protocol endpoints.

The shares jumped 11 percent the most since June 20, to 9.92 shekels at 11:41 a.m. in Tel Aviv, giving the Haifa, Israel-based company a market value of 426 million shekels ($116 million).

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.